239 related articles for article (PubMed ID: 23716562)
1. CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features.
Bisig B; de Reyniès A; Bonnet C; Sujobert P; Rickman DS; Marafioti T; Delsol G; Lamant L; Gaulard P; de Leval L
Haematologica; 2013 Aug; 98(8):1250-8. PubMed ID: 23716562
[TBL] [Abstract][Full Text] [Related]
2. [Expression of microRNA in ALK-negative anaplastic large cell lymphoma and CD30-positive peripheral T cell lymphoma, not otherwise specified].
Wang C; Chen X; Chen X; He Y; Cao L
Zhonghua Bing Li Xue Za Zhi; 2015 Aug; 44(8):565-70. PubMed ID: 26705180
[TBL] [Abstract][Full Text] [Related]
3. Expression of cytotoxic proteins in peripheral T-cell and natural killer-cell (NK) lymphomas: association with extranodal site, NK or Tgammadelta phenotype, anaplastic morphology and CD30 expression.
Kanavaros P; Boulland ML; Petit B; Arnulf B; Gaulard P
Leuk Lymphoma; 2000 Jul; 38(3-4):317-26. PubMed ID: 10830738
[TBL] [Abstract][Full Text] [Related]
4. JAK2 Rearrangements Are a Recurrent Alteration in CD30+ Systemic T-Cell Lymphomas With Anaplastic Morphology.
Fitzpatrick MJ; Massoth LR; Marcus C; Vergilio JA; Severson E; Duncan D; Ramkissoon SH; Hasserjian RP; Kim AS; Sohani AR; Williams EA; Nardi V
Am J Surg Pathol; 2021 Jul; 45(7):895-904. PubMed ID: 34105517
[TBL] [Abstract][Full Text] [Related]
5. Disturbed expression of the T-cell receptor/CD3 complex and associated signaling molecules in CD30+ T-cell lymphoproliferations.
Geissinger E; Sadler P; Roth S; Grieb T; Puppe B; Müller N; Reimer P; Vetter-Kauczok CS; Wenzel J; Bonzheim I; Rüdiger T; Müller-Hermelink HK; Rosenwald A
Haematologica; 2010 Oct; 95(10):1697-704. PubMed ID: 20511667
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels.
Bossard C; Dobay MP; Parrens M; Lamant L; Missiaglia E; Haioun C; Martin A; Fabiani B; Delarue R; Tournilhac O; Delorenzi M; Gaulard P; de Leval L
Blood; 2014 Nov; 124(19):2983-6. PubMed ID: 25224410
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the t(2;5)(p23;q35) translocation by reverse transcription-polymerase chain reaction in CD30+ anaplastic large-cell lymphomas, in other non-Hodgkin's lymphomas of T-cell phenotype, and in Hodgkin's disease.
Wellmann A; Otsuki T; Vogelbruch M; Clark HM; Jaffe ES; Raffeld M
Blood; 1995 Sep; 86(6):2321-8. PubMed ID: 7662979
[TBL] [Abstract][Full Text] [Related]
8. Defining signatures of peripheral T-cell lymphoma with a targeted 20-marker gene expression profiling assay.
Drieux F; Ruminy P; Abdel-Sater A; Lemonnier F; Viailly PJ; Fataccioli V; Marchand V; Bisig B; Letourneau A; Parrens M; Bossard C; Bruneau J; Dobay P; Veresezan L; Dupuy A; Pujals A; Robe C; Sako N; Copie-Bergman C; Delfau-Larue MH; Picquenot JM; Tilly H; Delarue R; Jardin F; de Leval L; Gaulard P
Haematologica; 2020 Jun; 105(6):1582-1592. PubMed ID: 31488561
[TBL] [Abstract][Full Text] [Related]
9. Peripheral T-cell lymphomas expressing CD30 and CD15 expand the spectrum of anaplastic large cell lymphoma, ALK-negative.
Ganapathi KA; Nicolae A; Egan C; Geng H; Xi L; Pack SD; McFadden JR; Raffeld M; Jaffe ES; Pittaluga S
Br J Haematol; 2024 Apr; ():. PubMed ID: 38613165
[TBL] [Abstract][Full Text] [Related]
10. Pathobiology and molecular profiling of peripheral T-cell lymphomas.
de Leval L; Gaulard P
Hematology Am Soc Hematol Educ Program; 2008; ():272-9. PubMed ID: 19074096
[TBL] [Abstract][Full Text] [Related]
11. CD30 expression in peripheral T-cell lymphomas.
Sabattini E; Pizzi M; Tabanelli V; Baldin P; Sacchetti CS; Agostinelli C; Zinzani PL; Pileri SA
Haematologica; 2013 Aug; 98(8):e81-2. PubMed ID: 23716537
[No Abstract] [Full Text] [Related]
12. Anaplastic large-cell lymphomas of B-cell phenotype are anaplastic lymphoma kinase (ALK) negative and belong to the spectrum of diffuse large B-cell lymphomas.
Haralambieva E; Pulford KA; Lamant L; Pileri S; Roncador G; Gatter KC; Delsol G; Mason DY
Br J Haematol; 2000 Jun; 109(3):584-91. PubMed ID: 10886208
[TBL] [Abstract][Full Text] [Related]
13. BCL10 down-regulation in peripheral T-cell lymphomas.
Rossi M; Agostinelli C; Righi S; Sabattini E; Bacci F; Gazzola A; Pileri SA; Piccaluga PP
Hum Pathol; 2012 Dec; 43(12):2266-73. PubMed ID: 22818167
[TBL] [Abstract][Full Text] [Related]
14. Peripheral T cell and natural killer (NK) T cell lymphomas: a clinicopathological study from a single Australian centre.
McKelvie PA; Thompson PA; Tam CS
Histopathology; 2012 Aug; 61(2):212-23. PubMed ID: 22716228
[TBL] [Abstract][Full Text] [Related]
15. High intratumoural galectin-1 expression predicts adverse outcome in ALK
Holst JM; Ludvigsen M; Hamilton-Dutoit SJ; Bendix K; Plesner TL; Nørgaard P; Møller MB; Steiniche T; Rabinovich GA; d'Amore F; Pedersen MB
Hematol Oncol; 2020 Feb; 38(1):59-66. PubMed ID: 31834627
[TBL] [Abstract][Full Text] [Related]
16. BCL-6 protein expression in human peripheral T-cell neoplasms is restricted to CD30+ anaplastic large-cell lymphomas.
Carbone A; Gloghini A; Gaidano G; Dalla-Favera R; Falini B
Blood; 1997 Sep; 90(6):2445-50. PubMed ID: 9310496
[TBL] [Abstract][Full Text] [Related]
17. CD30 expression in non-Hodgkin's lymphoma.
Piris M; Brown DC; Gatter KC; Mason DY
Histopathology; 1990 Sep; 17(3):211-8. PubMed ID: 2173674
[TBL] [Abstract][Full Text] [Related]
18. Cyclin D1 expression in peripheral T-cell lymphomas.
Song JY; Song L; Herrera AF; Venkataraman G; Murata-Collins JL; Bedell VH; Chen YY; Kim YS; Tadros R; Nathwani BN; Weisenburger DD; Feldman AL
Mod Pathol; 2016 Nov; 29(11):1306-1312. PubMed ID: 27469326
[TBL] [Abstract][Full Text] [Related]
19. Nodal cytotoxic lymphoma spectrum: a clinicopathologic study of 66 patients.
Kagami Y; Suzuki R; Taji H; Yatabe Y; Takeuchi T; Maeda S; Kondo E; Kojima M; Motoori T; Mizoguchi Y; Okamoto M; Ohnishi K; Yamabe H; Seto M; Ogura M; Koshikawa T; Takahashi T; Kurita S; Morishima Y; Suchi T; Nakamura S
Am J Surg Pathol; 1999 Oct; 23(10):1184-200. PubMed ID: 10524519
[TBL] [Abstract][Full Text] [Related]
20. Among diffuse large B-cell lymphomas, T-cell-rich/histiocyte-rich BCL and CD30+ anaplastic B-cell subtypes exhibit distinct clinical features.
Maes B; Anastasopoulou A; Kluin-Nelemans JC; Teodorovic I; Achten R; Carbone A; De Wolf-Peeters C;
Ann Oncol; 2001 Jun; 12(6):853-8. PubMed ID: 11484964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
